Table 1.
Demographic and clinical characteristics of the 165 perinatally HIV-infected children in the study population.
| Characteristic | Total (n=165) |
|---|---|
| Current† age, years, median (q1, q3) | 16.7 (15.9, 17.8) |
| Female, n (%) | 84 (51%) |
| Race/Ethnicity, n (%) | |
| White/Other | 12 (7%) |
| Black | 113 (68%) |
| Hispanic | 39 (24%) |
| Missing | 1 (1%) |
| Current† CD4 count, cells/mm3, n (%) | |
| <200 | 19 (12%) |
| 200–500 | 46 (28%) |
| >500 | 94 (57%) |
| Missing | 6 (4%) |
| Nadir CD4 count, cells/mm3, n (%) | |
| <200 | 68 (41%) |
| 200–500 | 81 (49%) |
| >500 | 16 (10%) |
| Current† HIV viral load, copies/mL, n (%) | |
| ≤ 400 | 98 (59%) |
| 401–5,000 | 25 (15%) |
| >5,000 | 35 (21%) |
| Missing | 7 (4%) |
| Peak HIV viral load, copies/mL, n (%) | |
| <10,000 | 7 (4%) |
| 10,000–100,000 | 45 (27%) |
| >100,000 | 113 (68%) |
| Current† CDC category, n (%) | |
| N/A | 59 (36%) |
| B | 55 (33%) |
| C | 51 (31%) |
| HAART | |
| Current† use, n (%) | 143 (87%) |
| Ever use, n (%) | 160 (97%) |
| Cumulative duration of use, years, median (q1, q3) | 11.0 (7.7, 12.5) |
| Boosted protease inhibitor | |
| Current† use, n (%) | 95 (58%) |
| Ever use, n (%) | 122 (74%) |
| Cumulative duration of use, years, median (q1, q3) | 4.0 (0.0, 7.4) |
| Lopinavir/ritonavir | |
| Current† use, n (%) | 48 (29%) |
| Ever use, n (%) | 95 (58%) |
| Cumulative duration of use, years, median (q1, q3) | 1.4 (0.0, 4.8) |
| Indinavir | |
| Current† use, n (%) | 0 (0%) |
| Ever use, n (%) | 18 (11%) |
| Cumulative duration of use, years, median (q1, q3) | 0.0 (0.0, 0.0) |
| Didanosine | |
| Current† use, n (%) | 17 (10%) |
| Ever use, n (%) | 138 (84%) |
| Cumulative duration of use, years, median (q1, q3) | 3.3 (1.0, 7.1) |
| Abacavir | |
| Current† use, n (%) | 46 (28%) |
| Ever use, n (%) | 79 (48%) |
| Cumulative duration of use, years, median (q1, q3) | 0.0 (0.0, 3.3) |
| Stavudine | |
| Current† use, n (%) | 11 (7%) |
| Ever use, n (%) | 136 (82%) |
| Cumulative duration of use, years, median (q1, q3) | 6.1 (1.8, 8.5) |
| Zidovudine | |
| Current† use, n (%) | 18 (11%) |
| Ever use, n (%) | 145 (88%) |
| Cumulative duration of use, years, median (q1, q3) | 3.7 (1.6, 7.4) |
| Lamivudine | |
| Current† use, n (%) | 53 (32%) |
| Ever use, n (%) | 149 (90%) |
| Cumulative duration of use, years, median (q1, q3) | 5.7 (2.8, 9.4) |
| Tenofovir disoproxil fumarate | |
| Current† use, n (%) | 80 (48%) |
| Ever use, n (%) | 100 (61%) |
| Cumulative duration of use, years, median (q1, q3) | 0.9 (0.0, 3.2) |
†
Current defined as measurement at most recent visit.
CDC: Centers for Disease Control and Prevention (N/A: not/mildly symptomatic, B: moderately symptomatic, C: severely symptomatic (AIDS definition)), HAART: highly active antiretroviral therapy.